A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2018

At a glance

  • Drugs Lebrikizumab (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors Dermira
  • Most Recent Events

    • 06 Aug 2018 According to a Dermira media release, complete enrolment is expected by the end of the year and announce top-line results in the first half of 2019.
    • 06 Aug 2018 According to a Dermira media release, study achieved the 50% enrollment mark, triggering a $25.0 million milestone obligation pursuant to the licensing agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc., which was paid in July 2018.
    • 04 May 2018 According to a Dermira media release, the company expects to complete the enrollment in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top